% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Johann:126797,
author = {P. Johann$^*$ and I. Müller},
title = {{M}ultipotent {M}esenchymal {S}tromal {C}ells: {P}ossible
{C}ulprits in {S}olid {T}umors?},
journal = {Stem cells international},
volume = {2015},
issn = {1687-9678},
address = {London [u.a.]},
publisher = {Sage-Hindawi},
reportid = {DKFZ-2017-02825},
pages = {914632},
year = {2015},
abstract = {The clinical use of bone marrow derived multipotent
mesenchymal stromal cells (BM-MSCs) in different settings
ranging from tissue engineering to immunotherapies has
prompted investigations on the properties of these cells in
a variety of other tissues. Particularly the role of MSCs in
solid tumors has been the subject of many experimental
approaches. While a clear phenotypical distinction of tumor
associated fibroblasts (TAFs) and MSCs within the tumor
microenvironment is still missing, the homing of bone marrow
MSCs in tumor sites has been extensively studied. Both,
tumor-promoting and tumor-inhibiting effects of BM-MSCs have
been described in this context. This ambiguity requires a
reappraisal of the different studies and experimental
methods employed. Here, we review the current literature on
tumor-promoting and tumor-inhibiting effects of BM-MSCs with
a particular emphasis on their interplay with components of
the immune system and also highlight a potential role of
MSCs as cell of origin for certain mesenchymal tumors.},
cin = {B062},
ddc = {610},
cid = {I:(DE-He78)B062-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26273308},
pmc = {pmc:PMC4530290},
doi = {10.1155/2015/914632},
url = {https://inrepo02.dkfz.de/record/126797},
}